Efficacy and side effects of antiplatelets with anticoagulants in Coronary Artery Ectasia

Evaluation of the efficacy and side effects of anti platelets in comparison with anti coagulation in coronary artery ecstasia patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210110049984N1

Enrollment

148

Registered

2021-10-25

Start date

2021-09-19

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ectatic coronary artery. Abnormal balloon- or sac-like dilatation in the wall of coronary vessels. Most coronary aneurysms are due to coronary atherosclerosis, and the rest are due to inflammatory diseases

Interventions

Intervention 1: Intervention group: Patients with coronary artery ectasia who have undergone stenting are treated with aspirin 80 mg daily, clopidogrel 75 mg daily, and rivaroxaban 2.5 mg twice dai

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ectatic coronary artery in angiography

Exclusion criteria

Exclusion criteria: History of taking anticoagulant drug Coagulation disorder Hepatic failure Renal failure

Design outcomes

Primary

Measure	Time frame
Myocardial infarction. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.;Stroke. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.;Mortality. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.;Major bleeding. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.;Minor bleeding. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.	—

Measure

Time frame

Myocardial infarction. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.;Stroke. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.;Mortality. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.;Major bleeding. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.;Minor bleeding. Timepoint: Up to one year from the intake of the medication. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehnoush pourkarimi fatideh

Zanjan University of Medical Sciences

info.behnoosh@gmail.com+98 24 3313 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026